Cobalamin in inflammation III - Glutathionylcobalamin and methylcobalamin/adenosylcobalamin coenzymes: The sword in the stone? How cobalamin may directly regulate the nitric oxide synthases

Journal of Nutritional and Environmental Medicine

Volumn 16, Issue 3-4, 2007, Pages 212-226

  Wheatley, Carmen ^a  

^a Orthomolecular Oncology   (United Kingdom)

Author keywords

Adenosylcobalamin; Arginine; cP450; Glutathionylcobalamin; Imidazoles; Inducible neuronal endothelial nitric oxide synthases; Methionine synthase; Methylcobalamin; Methylmalonyl CoA mutase; N G hydroxy l arginine; Phorphyrin corrin NOS monoxygenation

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ARGININE; BETA INTERFERON; COBALAMIN; COBAMAMIDE; CYTOCHROME P450; FERRIC ION; GLUTATHIONYLCOBALAMIN; MECOBALAMIN; METHIONINE SYNTHASE; METHYLMALONYL COENZYME A MUTASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; COENZYME; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; ENZYME BINDING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HUMAN; MALARIA; NEOPLASM; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

ANAGALLIS ARVENSIS;

EID: 38849169473     PISSN: 13590847     EISSN: 13646907     Source Type: Journal    
DOI: 10.1080/13590840701791863     Document Type: Article

References (64)

1. Peracchi M, Bamonti Catena F, Pomati M, et al. Human cobalamin deficiency: alterations in serum tumour necrosis factor-α and epidermal growth factor. Eur J Haematol 2001;67:123-7.
2. Scalabrino G, Corsi MM, Veber D, et al. Cobalamin (vitamin B12) positively regulates interleukin-6 levels in rat cerebrospinal fluid. J Neuro-immunol 2002;127:37-43.
3. Scalabrino G, Mutti E, Veber D. Increased spinal cord NGF levels in rats with cobalamin (vitamin B12) deficiency. Neurosci Lett 2006;396:153-8.
4. Sakone T, Takada S, Kotani H, Tsunematsu T. Effects of methyl-B12 on the in vitro immune functions of human T lymphocytes. J Clin Immunol 1982;2:101-9.
5. Tamura J, Kubota K, Murakami H, et al. Immunomodulation by vitamin B12 augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. Clin Exp Immunol 1999;116:28-32.
6. Wheatley C. A Scarlet Pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock. Med Hypotheses 2006;67:124-42.
7. Wheatley C. The return of the Scarlet Pimpernel. Cobalamin in inflammation II: cobalamins can both selectively promote all three nitric oxide synthases (NOS), particularly iNOS and eNOS, and, as needed, selectively inhibit iNOS and nNOS. J Nutr Environ Med 2007;16:181-211.
8. Rachmilewitz D, Ligumsky M, Rachmilewitz B, et al. Transcobalamin II level in peripheral blood monocytes - a biochemical marker in inflammatory diseases of the bowel. Gastroenterology 1980;78:43-6.
9. Ling CT, Chow BF. Effect of vitamin B12 on the levels of soluble sulfhydryl compounds in blood. J Biol Chem 1953;202:445-56.
10. Register UD. The effect of vitamin B12 on liver and blood non-protein sulfhydryl compounds. J Biol Chem 1954;206:705-9.
11. Xia L, Cregan AG, Berben LA, Brasch NE. Studies on the formation of glutathionylcobalamin: any free intracellular aquacobalamin is likely to be rapidly and irreversibly converted to glutathionylcobalamin. Inorg Chem 2004;43:6848-57.
12. Suto RK, Brasch NE, Anderson OP, Finke RG. Synthesis, characterization, solution stability and X-ray crystal structure of the thiolatocobalamin γ-glutamylcysteinylcobalamin, a dipeptide analog of glutathionylcobalamin: insights into the enhanced Co-S bond stability of the natural product glutathionylcobalamin. Inorg Chem 2001;40:2686-92.
13. Dubnoff JW, Bartron E. The effect of B12 on enzyme activity in E. coli mutant 113-3. Arch Biochem Biophys 1956;61:99-110.
14. Pezacka E, Green R, Jacobsen DW. Glutathionylcobalamin as an intermediate in the formation of cobalamin coenzymes. Biochem Biophys Res Comm 1990;169(2):443-50.
15. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox activated forms. Science 1992;258:1898-902.
16. Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as an s-nitroso adduct of serum albumin. Proc Natl Acad Sci 1992;89:7674-7.
17. Singh SP, Wishnok JS, Keshive M, Deen WM, Tannenbaum SR. The chemistry of the s-nitroso-glutathione/ glutathione system. Proc Natl Acad Sci 1996;93:14428-33.
18. Ji Y, Akerboom TPM, Sies H, Thomas JA. S-Nitrosylation and S-glutathionylation of protein sulfhydryls by S-nitroso glutathione. Arch Biochem Biophys 1999;362:67-78.
19. Zheng D, Birke RL. The reaction of nitric oxide with glutathionylcobalamin. J Am Chem Soc 2002;124:9066-7.
20. Luschinsky Drennan C, Huang S, Drummond JT, Matthews RG, Ludwig ML. How a protein binds B12: a 3.0Å X-ray structure of B12-binding domains of methionine synthase. Science 1994;266:1669-74.
21. Mancia F, Keep NH, Nakagawa A, et al. How coenzyme B12 radicals are generated: the crystal structure of methylmalonyl-coenzyme A mutase at 2Å resolution. Structure 1996;4(3):339-49.
22. Zheng D, Yan L, Birke RL. Electrochemical and spectral studies of the reactions of aquacobalamin with nitric oxide and nitrite ion. Inorg Chem 2003;41:2548-55.
23. Riches DWH, Underwood GA. Expression of interferon-beta during the triggering phase of macrophage cytocidal activation. J Biol Chem 1991;266:24785-92.
24. Crane BR, Arvai AS, Gachui R, et al. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science 1997;278:425-31.
25. Crane BR, Arvai AS, Ghosh DK, et al. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 1998;279:2121-6.
26. Fischmann TO, Hruza A, Niu XD, et al. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 1999;6:233-42.
27. Li H, Raman CS, Glaser CB, et al. Crystal structures of zinc-free and -bound heme domain of human inducible nitric oxide synthase. Implications for dimer stability and comparison with endothelial nitric oxide synthase. J Biol Chem 1999;274:21276-84.
28. Raman CS, Li H, Martasek P, Kral V, Masters BS, Poulos TL. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 1998;95:939-50.
29. Tierney DL, Huang H, Martasek P, et al. ENDOR studies of l-arginine and N-G-hydroxyl-l-arginine bound to all three holo-nitric oxide synthase isoenzymes. J Am Chem Soc 2000;122:5405-6.
30. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function, and inhibition. Biochem J 2001;357:593-615.
31. Salerno JC, Harris DE, Irizarry K, et al. An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase. J Biol Chem 1997;272:29769-29777.
32. Martásek P, Miller RT, Roman LJ, Shea T, Masters BSS. Assays of isoforms of E. coli-expressed nitric oxide synthase. Meth Enzymol 1999;301:70-8.
33. Raman CS, Li H, Martasek P, Kral V, Masters BS, Poulos TL. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 1998;95:939-50.
34. Albakri QA, Stuehr DJ. Intracellular assembly of inducible NO synthase is limited by nitric oxide - mediated changes in heme insertion and availability. J Biol Chem 1996;271(10):5414-21.
35. Sennequier N, Wolan D, Stuehr DJ. Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem 1999;274:930-8.
36. McMillan K, Adler M, Auld DS, et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci 2000;97:1506-11.
37. Berka V, Chen PF, Tsai AL. Spatial relationship between l-arginine and heme binding sites of endothelial nitric-oxide synthase. J Biol Chem 1996;271:33293-3300.
38. Chabin RM, McCauley E, Calaycay JR, et al. Active-site structure analysis of recombinant human inducible nitric oxide synthase using imidazole. Biochemistry 1996;35:9567-75.
39. Wolff DJ, Datto GA, Samatovicz RA, Tempsick RA. Calmodulin-dependent nitric-oxide synthase. Mechanism of inhibition by imidazole and phenylimidazoles. J Biol Chem 1993;268:9425-9.
40. Groves JT, Wang CC-Y. Nitric oxide synthase: models and mechanisms. Curr Opin Chem Biol 2000;4:687-95.
41. Swanson RA, Dus KM. Specific covalent labeling of cytochrome P-450CAM with 1-(4-azidophenyl)imidazole, an inhibitor-derived photoaffinity probe for P-450 heme proteins. J Biol Chem 1979;254:7238-46.
42. Roman LJ, Martasek P, Miller TR, et al. The C termini of constitutive nitric oxide synthases control electron flow through the flavin and heme domains and affect modulation by calmodulin. J Biol Chem 2000;275:29225-32.
43. Masters BS. Structural variations to accommodate functional themes of the isoforms of NO synthases. In: Ignarro LJ, editor. Nitric oxide: biology and pathobiology San Diego: Academic Press; 2000. pp 91-104.
44. Sirovatka JM, Finke RG. Coenzyme B12 chemical precedent studies: probing the role of the imidazole baseon motif found in B12-dependent methylmalonyl-CoA mutase. J Am Chem Soc 1997;119:3057-67.
45. Gruber K, Jogl G, Klintschar G, Kratky C. High resolution crystal structures of cobalamins. In: Kräutler B, Arigoni D, Golding BT, editors. Vitamin B12 and B12 proteins Weinheim: Wiley; 1999. pp 335-47.
46. Scheuring EM, Sagi I, Chance MR. Sulfur-containing cobalamins: x-ray absorption spectroscopic characterization. Biochemistry 1994;33:6310-5.
47. Couture M, Stuehr DJ, Rousseau DL. The ferrous dioxygen complex of the oxygenase domain of neuronal nitric oxide synthase. J Biol Chem 2000;275:3102-205.
48. Marletta MA, Hurshman AR, Rusche KM. Catalysis by nitric oxide synthase. Curr Opin Chem Biol 1998;2:656-63.
49. Perry JM, Marletta MA. Effects of transition metals on nitric oxide synthase catalysis. Proc Natl Acad Sci 1998;95:11101-6.
50. Kolb-Bachofen V, Kröncke K-D, Fehsel K, Suschek C. Role of inducible nitric oxide synthase in autoimmune or other immune-mediated diseases. In: Ignarro LJ, editor. Nitric oxide: biology and pathobiology San Diego: Academic Press; 2000. pp 811-21.
51. Alderton WK, Boyham A, Lowe PN. Nitroarginine and tetrahydrobiopterin binding to the haem domain of neuronal nitric oxide synthase using a scintillation proximity assay. Biochem J 1998;332:195-201.
52. Gardner PR. Nitric oxide dioxygenase function and mechanism of flavohemoglobin, hemoglobin, myoglobin and their associated reductases. J Inorg Biochem 2005;99(1):247-66.
53. Helmick RA, Fletcher AE, Gardner AM, et al. Imidazole antibiotics inhibit the nitric oxide dioxygenase function of microbial flavohemoglobin. AAC 2005;49(5):1837-43.
54. Yamashiki M, Nishimura A, Kosaka Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J Clin Lab Immunol 1992;37:173-82.
55. 4 receptors and SpI transcription factor binding sites. J Biol Chem 2005;280:29993-30000.
56. Bauer J, Morrison BH, Grane R, et al. Effects of interferon β on transcobalamin II-receptor expression and anti-tumor activity of nitrosylcobalamin. J Natl Cancer Inst 2002;94(13):1010-9.
57. Poydock M. Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumours. Exp Cell Biol 1979;47:210-7.
58. Poydock ME, Harguindey S, Hart T, Takita H, Kelly D. Mitogenic inhibition and effect of survival of mice bearing L1Z10 leukemia using a combination of dehydroascorbic acid and hydroxocobalamin. Am J Clin Oncol 1985;8:266-9.
59. Nishizawa Y, Yamamoto T, Terada N, et al. Effects of methylcobalamin on the proliferation of androgensensitive or estrogen-sensitive malignant cells in culture and in vivo. Int J Vitam Nutr Res 1997;67:164-70.
60. Tsao C, Miyashita K, Yang M. Cytotoxic activity of cobalamin in cultured malignant cells. Pathobiology 1990;58:292-6.
61. Bodian M. Neuroblastoma. Pediatr Clin North Am 1959;6:449-72.
62. Wheatley C. Multiple myeloma: the case of the .005% survivor. In: Gearin-Tosh M. Living proof, London: Simon and Schuster.
63. Wheatley C. A unified theory of the causes of monoclonal gammopathy of unknown significance (MGUS) and multiple myeloma, with a consequent treatment proposal for long-term control and possible cure. J Ortho Med 2002;1:7-16.
64. Cruz T, Pastrak A. Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory disease. US Patent Application. Pub no. US2005/0163751 A1.